Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia
Andres Chang, Anton M. Sholukh, Andreas Wieland, David L. Jaye, Mary Carrington, Meei-Li Huang, Hong Xie, Keith R. Jerome, Pavitra Roychoudhury, Alexander L. Greninger, Jean L. Koff, Jonathon B. Cohen, David M. Koelle, Lawrence Corey, Christopher R. Flowers, Rafi Ahmed
Andres Chang, Anton M. Sholukh, Andreas Wieland, David L. Jaye, Mary Carrington, Meei-Li Huang, Hong Xie, Keith R. Jerome, Pavitra Roychoudhury, Alexander L. Greninger, Jean L. Koff, Jonathon B. Cohen, David M. Koelle, Lawrence Corey, Christopher R. Flowers, Rafi Ahmed
View: Text | PDF
Clinical Research and Public Health Hematology Immunology

Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia

  • Text
  • PDF
Abstract

Background Herpes simplex virus lymphadenitis (HSVL) is an unusual presentation of HSV reactivation in patients with chronic lymphocytic leukemia (CLL) and is characterized by systemic symptoms and no herpetic lesions. The immune responses during HSVL have not, to our knowledge, been studied.Methods Peripheral blood and lymph node (LN) samples were obtained from a patient with HSVL. HSV-2 viral load, antibody levels, B and T cell responses, cytokine levels, and tumor burden were measured.Results The patient showed HSV-2 viremia for at least 6 weeks. During this period, she had a robust HSV-specific antibody response with neutralizing and antibody-dependent cellular phagocytotic activity. Activated (HLA-DR+, CD38+) CD4+ and CD8+ T cells increased 18-fold, and HSV-specific CD8+ T cells in the blood were detected at higher numbers. HSV-specific B and T cell responses were also detected in the LN. Markedly elevated levels of proinflammatory cytokines in the blood were also observed. Surprisingly, a sustained decrease in CLL tumor burden without CLL-directed therapy was observed with this and also a prior episode of HSVL.Conclusion HSVL should be considered part of the differential diagnosis in patients with CLL who present with signs and symptoms of aggressive lymphoma transformation. An interesting finding was the sustained tumor control after 2 episodes of HSVL in this patient. A possible explanation for the reduction in tumor burden may be that the HSV-specific response served as an adjuvant for the activation of tumor-specific or bystander T cells. Studies in additional patients with CLL are needed to confirm and extend these findings.Funding NIH grants 4T32CA160040, UL1TR002378, and 5U19AI057266 and NIH contracts 75N93019C00063 and HHSN261200800001E. Neil W. and William S. Elkin Fellowship (Winship Cancer Institute).

Authors

Andres Chang, Anton M. Sholukh, Andreas Wieland, David L. Jaye, Mary Carrington, Meei-Li Huang, Hong Xie, Keith R. Jerome, Pavitra Roychoudhury, Alexander L. Greninger, Jean L. Koff, Jonathon B. Cohen, David M. Koelle, Lawrence Corey, Christopher R. Flowers, Rafi Ahmed

×

Figure 3

Robust T cell and plasma cytokine responses were observed.

Options: View larger image (or click on image) Download as PowerPoint
Robust T cell and plasma cytokine responses were observed.
(A) FACS plot...
(A) FACS plots of singlet, live, CD3+, CD4+, and CD8+ lymphocytes at baseline and on day +5, identifying activated HLA-DR+CD38+ T cells. (B) Percentage of activated CD4+ (purple) and CD8+ (orange) T cells over time as analyzed in A. (C) FACS analysis showing a high percentage of activated CD4+ and CD8+ T cells in the LN. Numbers in A and C denote the percentage of total CD4+ or CD8+ T cells. (D) CD38+HLA-DR+ T cells in the blood (red) had an effector phenotype. Numbers denote a percentage of activated CD4+ or CD8+ T cells expressing or downregulating the marker of interest. Naive (black) CD4+ or CD8+ T cells are shown as a control. All gates were set in reference to naive CD4+ or CD8+ T cells. (E) UL-25 tetramer staining in the blood on day +5 and day +270. Numbers denote the percentage of total CD8+ T cells. (F) Percentage of HSV-2 UL-25–specific tetramer+CD8+ T cells in the blood over time. (G) Extended phenotype analysis of UL-25 tetramer+CD8+ T cells in the blood on day 5. Green indicates UL-25 tetramer+CD8+ T cells; black indicates naive CD8+ T cells. Numbers indicate the percentage of tetramer+ (green) CD8+ T cells. Mean plasma levels of proinflammatory cytokines IFN-γ (H), IL-18 (I), and IL-6 (J) were elevated in the acute setting. All measurements were performed in quadruplicate. Error bars indicate the SD. Horizontal dotted line indicates the levels in pooled plasma from aged-matched healthy individuals. For all applicable graphs, the vertical dotted line indicates the time of presentation. Day, days since symptom onset. Rel Freq, relative frequency.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts